US EditionPublished • loading... • Updated
Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
Summary by Helena Independent Record
30 Articles
30 Articles
Helena Independent Record+28 Reposted by 28 other sources
Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide groupDREAMS-3 is
·Helena, United States
Read Full Article
Coverage Details
Total News Sources30
Leaning Left1Leaning Right1Center15Last UpdatedBias Distribution88% Center
Bias Distribution
- 88% of the sources are Center
88% Center
C 88%
Factuality
To view factuality data please Upgrade to Premium
